Tumor Markers in Ovarian Cancer

Abstract

Even if today’s society is rapidly evolving there is still much that can be done. This applies in theoncological field. One of the main female health problems worldwide is represented by thegynecological cancers. Ovarian cancer is the main cause of mortality among women withgynecological cancers. Although its prevalence is lover compared to breast, uterine or cervicalcancer, the mortality and morbidity rates are significantly higher. The first step in the managementof ovarian cancer is represented by regular screening and rapid diagnosis. One of the most importanttolls is represented by serological markers dosage in order to estimate the type of tumor before thegynecological specific intervention. There is a real need to identify correctly the ovarian cancer asearly as possible in order to obtain the favorable prognosis that comes with the diagnosis in earlystage. Most of the ovarian cancers (above 90%) are represented by carcinomas which are frequentlydiagnosed in advanced stages. The roles of the biomarkers are to indicate the malignancy of anovarian tumor and to predict the relapse risk. The aim of this paper is to update the indicationsregarding the usage of serological markers in ovarian cancers and the importance of using them forour patients.

Laparoscopic myomectomy – The importance of surgical techniques

“…Uterine artery embolization is a convenient method to spare the uterus if a patient experiences substantial bleeding ( 4 ). In addition to potential complications associated with uterine artery embolization, the main concern is damage to the ovarian vascular supply ( 5 ). The symptomatology of uterine leiomyoma is one of the main factors determining the treatment protocol ( 6 ).…”

Integrated transcriptomic and metabolomic investigation of the genes and metabolites involved in swine follicular cyst formation

“…Increased LDHB expression indicates up-regulation of glycolysis, which is closely related to activation of primary follicles ( 28 ). LDH is also used as a marker for ovarian tumors ( 29 ); serum LDH is significantly higher in patients with malignant ovarian cancer than in patients with benign ovarian tumors ( 30 ). In our study, the LDHB gene was significantly up-regulated in the TIMG cells of follicular cysts, and there was a mutation in the 5′-untranslated region of LDHB, indicating that increased LDH correlated with the occurrence of follicular cysts.…”